Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Stock Has Average Price Target of $3.83

Posted by Francis Steltz on Oct 9th, 2026

Nautilus Biotechnology, Inc. (NASDAQ:NAUT – Get Free Report) has earned an average rating of “Moderate Buy” from the five research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $3.83.

A number of research analysts recently issued reports on the company. Roth Capital started coverage on Nautilus Biotechnology in a research note on Tuesday, September 29th. They set a “buy” rating and a $3.50 price target on the stock. Leerink Partners assumed coverage on Nautilus Biotechnology in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $4.00 price objective for the company. Weiss Ratings lowered shares of Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 5th. Finally, Zacks Research raised shares of Nautilus Biotechnology to a “hold” rating in a report on Wednesday, September 30th.

Read Our Latest Analysis on Nautilus Biotechnology

Institutional Trading of Nautilus Biotechnology

A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in shares of Nautilus Biotechnology during the second quarter worth approximately $5,025,000. Susquehanna International Group LLP grew its position in Nautilus Biotechnology by 1,710.9% in the 2nd quarter. Susquehanna International Group LLP now owns 890,949 shares of the company’s stock valued at $1,666,000 after buying an additional 841,749 shares during the last quarter. Corient Private Wealth LP purchased a new position in Nautilus Biotechnology in the 2nd quarter valued at $308,000. Bank of New York Mellon Corp acquired a new position in Nautilus Biotechnology in the 2nd quarter valued at $229,000. Finally, GSA Capital Partners LLP acquired a new position in Nautilus Biotechnology in the 2nd quarter valued at $189,000. 50.71% of the stock is owned by institutional investors and hedge funds.

Nautilus Biotechnology Price Performance

NASDAQ NAUT opened at $1.82 on Friday. Nautilus Biotechnology has a 1 year low of $0.82 and a 1 year high of $4.31. The company has a market capitalization of $231.59 million, a PE ratio of -4.04 and a beta of 0.73. The company has a fifty day moving average of $1.06 and a two-hundred day moving average of $1.98.

Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) last issued its quarterly earnings data on Monday, July 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.03. The firm had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.10 million. On average, research analysts expect that Nautilus Biotechnology will post -0.52 earnings per share for the current year.

About Nautilus Biotechnology

(Get Free Report)

Nautilus Biotechnology, Inc is a life sciences technology company developing tools for large-scale protein analysis. Its goal is to enable more comprehensive, sensitive and efficient study of the proteome, the full set of proteins expressed by a biological system, to support research in drug discovery, disease biology and translational science.

The company’s primary offering is the Nautilus Proteome Analysis Platform, which combines a proprietary analytical instrument, consumables and software.